Prof. Lucy Ogbadu is the director-general of the National Biotechnology Development Agency (NABDA). In his interview with NKECHI ISAAC, she talks about the current state of agricultural biotechnology development in Nigeria.
How many confined field trials are currently going on in Nigeria?
We have four confined field trials presently going on in Nigeria. They are BT Cowpea in Ahmadu Bello University, Institute of Agricultural Research, Zaria; African Bio-fortified Sorghum going on at the Ahmadu Bello University, Institute of Agricultural Research; BT Cotton equally being handled by IAR, Zaria; Newest Rice being handled by the National Cereals Research Institute, Badeggi.
How are the crops doing, how will you access their performance?
They are doing very well, were impressed with their performance. The BT Cowpea and ABS are ahead of the other two in the sense that they started earlier in 2011 and they have progressed tremendously. They are already into multi-locational trials as well as on-farm trials, especially the BT Cowpea.
When are you looking at harvesting these crops?
We harvest them periodically because there is no staple crop that grows for this length of time from 2011. So, obviously weve been harvesting and collecting the data on them, so it is not the issue of when we harvest because none of them grows more than a period of four to five months. So, weve been harvesting and studying them further.
When are we looking at commercialising these crops, the target was previously 2018 but it has been shifted to 2019. Can the nation make this new timeline?
The BT Cowpea will most likely be the first to go out for commercialisation and it will not go beyond 2019 in the sense that we want to be doubly sure on all were doing with the crop. The scientists are happy with the results they are getting, the farmers working with the scientists are equally happy with the results theyre getting in terms of out-performing the conventional ones theyve been used to. So, hopefully by 2019 latest, it should be out in the market.
Are there any regulatory hurdles that remain before these crops can be successfully commercialised in Nigeria?
Looking from the perspective of the government in terms of policy, there are no hurdles because the establishment of this agency by the government shows the government is in support of biotechnology. Now in terms of regulation all the risk assessment, all stewardship in terms of its performance have all been carried out by our scientists that are handling the crops.
This is about the last stage of what they need to do before it is commercialised in the sense that the seeds need to be multiplied before we can say they are ready for release but of course other regulatory hurdle that may interest you is that of registration of the crop with our varietal release committee, a unit based at Ibadan which will require them to convene a meeting of the varietal release committee to look at all the descriptors that are required to be looked at before they are registered and adjudged ready for release. That is about the only hurdle that is left.
After commercialization, how accessible will this crop be to the local farmers at the grassroots who are supposed to be the main benefactors of this technology?
They wont be different from all other seeds in the sense that once they are considered okay for commercial release then it will be at the national centre for genetic resources and biotechnology in Ibadan and at that stage the only thing that will be left will be for multiplication. You know the PIs will handle the multiplication along with the extension workers after which they will be ready for uptake for farmers that are interested and other interested people.
Seed companies are sceptical about genetically modified seeds, theyre scared that multinational seed companies like Monsanto and the likes will take over their market once GM crops are produced?
The process were currently adopting shows that our scientists and farmers are involved. Now if it gets to the stage of uptake and our indigenous Nigerian seed companies refuse to come forward to take them for multiplication and release them they shouldnt blame other seed companies that come forward to multiply them. In this case our own seed companies will definitely participate in the multiplication and release. I am sure of that. They should be able to come forward and participate because the qualities of the seeds are attractive so they should be able to come forward and take them up.
No foreign seed company will jump over the laid down protocols to come and introduce any foreign seed to Nigeria, it is not possible because the regulatory framework is in place to ensure that does not happen.
Some school of thoughts believe we should channel efforts at reducing food wastage instead of applying biotechnology to boost agriculture and ensure food security. What is your take on this?
Agricultural biotechnology is not limited to GMO alone. In fact the same technology can be applied to crops in order to check the food wastage, prolong the shelf life of agricultural produce, it can be applied to crops to ensure that improved yield of crops. So, there are various ways this technology can be used advantageously on crops. It can also be used to improve the nutritional quality of the crops. So, it is not limited to GM and as a matter of fact GM is only a technique that can give us so many other advantages. This is why we feel the public should trust our scientists enough to leave the matter to them because it is a complex scientific process that people who do not really understand science cant understand. The same technology can be used to improve the shelf life of tomato for instance such that it can stay on the shelf for much longer period without spoiling.
We cannot make any serious progress in agriculture without applying biotechnology; were talking about using agriculture to diversify Nigerias economy, if that is so how else other than mechanisation. In addition to mechanisation you must have quality seeds, deploy technology in order to use agriculture to diversify the economy. It is not with our crude system of agriculture that we can use it to diversify the economy. What this simply means is that were losing a lot if we do not use advanced technology, which is agricultural biotechnology to diversify the economy.
Through advanced agricultural biotechnology we can revolutionise agriculture and ensure food security using agricultural biotechnology. To downplay on it means the nation is losing heavily and invariably unserious about diversifying the economy through agriculture. Theres no other way, it is through agricultural biotechnology that we can inject and revolutionise agriculture to diversify Nigerias economy.
Follow this link:
We Can't Diversify Economy Through Agriculture Without Biotechnology Ogbadu - Leadership Newspapers
- NSF Funding is Key to the Biotechnology Workforceand National Security - New America - May 6th, 2025
- Matica Biotechnology and Texas A&M's NCTM Form Strategic Partnership to Deliver End-to-End Support for Cell and Gene Therapy Innovators - PR Newswire - May 6th, 2025
- Shareholders that lost money on Sana Biotechnology, Inc.(SANA) Urged to Join Class Action - Contact The Gross Law Firm to Learn More - PR Newswire - May 6th, 2025
- ETSU helps shape the future of U.S. biotechnology - East Tennessee State University - May 6th, 2025
- Matica Biotechnology and Texas A&M's NCTM Form Strategic Partnership to Deliver End-to-End Support for Cell and Gene Therapy Innovators - Citizen... - May 6th, 2025
- Halozyme to Participate in the BofA Securities 2025 Healthcare Conference - Quantisnow - May 6th, 2025
- Red Biotechnology Market to Witness Remarkable Growth with - openPR.com - May 6th, 2025
- Enabling next-generation anaerobic cultivation through biotechnology to advance functional microbiome research - Nature - May 6th, 2025
- Sana Biotechnology, Inc. Class Action: Levi & Korsinsky Reminds Sana Biotechnology, Inc. Investors of the Pending Class Action Lawsuit with a Lead... - May 6th, 2025
- Epicrispr Biotechnologies Announces Five Presentations Highlighting Advances in Epigenetic Modulation and AAV Manufacturing at ASGCT 2025 Annual... - May 6th, 2025
- Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025 - Quantisnow - May 6th, 2025
- Opinion: Canada should invest in itself instead of subsidizing foreign biotechnology companies - The Globe and Mail - April 14th, 2025
- National Commission Outlines Six Ways to Turbocharge U.S. Biotech Innovation Against the Threat from China - Genetic Engineering and Biotechnology... - April 14th, 2025
- Cereno Scientific to attend BIO International Convention 2025 - largest and most comprehensive event for biotechnology - TradingView - April 14th, 2025
- The Future of Plant Biotechnology Services: Market Expected to Reach USD 42.07 Billion by 2032 with 12.8% CAGR - openPR.com - April 14th, 2025
- Understanding the National Security Commission on Emerging Biotechnology Report - CSIS | Center for Strategic and International Studies - April 14th, 2025
- Congressional commission urges $15B, more action to maintain US biotech advantage over China - Fierce Biotech - April 14th, 2025
- Novonesis Poised to Accelerate National Security Commission Priorities on Biotechnology - PR Newswire - April 14th, 2025
- Class Action Filed Against Sana Biotechnology, Inc. (SANA) Seeking Recovery for Investors - Contact Levi & Korsinsky - PR Newswire - April 14th, 2025
- The Future of Mining with AI and Biotechnology Solutions - MSN - April 14th, 2025
- Padilla, Congressional Biotech Commission Introduce Bipartisan Bill to Bolster U.S. Biotechnology Innovation and Economy - Senator Alex Padilla (.gov) - April 14th, 2025
- US commission says $15B biotech investment is needed to maintain dominance over China - FirstWord Pharma - April 14th, 2025
- Senator Young Warns of Biotechnology Competition with China - WIBC - April 14th, 2025
- Research shows need for better mpox protection in HIV-positive patients - The Pharma Letter - April 5th, 2025
- Marine Biotechnology Market to Reach $10.37 Bn by 2032 with 6.2% CAGR - openPR.com - April 5th, 2025
- Robbins LLP Reminds SANA Investors with Large Losses to Contact the Firm for Information About the Securities Fraud Class Action Against Sana... - April 5th, 2025
- Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class... - April 5th, 2025
- Tech Trends 2030: How AI, Quantum Computing, and Biotechnology Will Shape the Future - Analytics Insight - February 24th, 2025
- The Security Implications of Developments in Biotechnology - International Institute for Strategic Studies - February 24th, 2025
- Biotechnology Permits and Notifications - USDA APHIS - February 24th, 2025
- Sustained in situ protein production and release in the mammalian gut by an engineered bacteriophage - Nature.com - February 24th, 2025
- Internal cap-initiated translation for efficient protein production from circular mRNA - Nature.com - February 24th, 2025
- MIT class takes students on a grand tour of the interdisciplinary world of biotech - MIT News - February 24th, 2025
- BioTech Breakthrough Awards BostonGene With Cancer Immunology Solution of the Year - Business Wire - February 24th, 2025
- Biodiversity to Bioeconomy - PIB - February 24th, 2025
- Luxa Biotechnology Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to RPESC-RPE-4W Transplantation for the Treatment... - February 24th, 2025
- Biofach 2025: Biosan Biotechnology CEO talks popular mushroom blends and wellness benefits - Nutrition Insight - February 24th, 2025
- Pushing the boundaries of biotechnology - UC Santa Cruz - January 27th, 2025
- Living with the Land Biotechnology Lab Now Blocked by Scrims & More: Daily Recap (1/26/25) - WDW News Today - January 27th, 2025
- Living with the Land Biotechnology Lab Now Blocked by Scrims in EPCOT - WDW News Today - January 27th, 2025
- Biotechnology led to dramatic innovations in agriculture and human health in 2024 - Genetic Literacy Project - January 27th, 2025
- Cultured algae and biotechnology are ingredients to the 'Gelato of the future' - STIRworld - January 27th, 2025
- New U.S. Export Controls Seek to Prevent China From Weaponizing Biotech - Foundation for Defense of Democracies - January 27th, 2025
- Fresh from the biotech pipeline: FDA approvals settle in 2024, but what next? - Nature.com - January 27th, 2025
- Nuevocor Welcomes Andreas Wallnfer as Chairman of the Board of Directors - Kilgore News Herald - January 27th, 2025
- Creating and sustaining university biotech spin-outs - PMLiVE - January 27th, 2025
- IMTECH celebrates 41st foundation day with focus on BioE3 policy and biotechnology innovations - The Times of India - January 27th, 2025
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance - November 16th, 2024
- Department of Biotechnology Launches Webinar Series on Biomanufacturing and Biofoundry Initiative - IBG NEWS - November 16th, 2024
- Multimodal scanning of genetic variants with base and prime editing - Nature.com - November 16th, 2024
- NEW INITIATIVE BY THE ITALIAN EMBASSY IN WASHINGTON ON BIOTECHNOLOGY WITH THE MILKEN INSTITUTE AND LEADING RESEARCHERS AND INDUSTRY EXPERTS -... - November 16th, 2024
- Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at... - November 16th, 2024
- Albany State offers new Master of Science in Integrated Biotechnology program - The Albany Herald - November 16th, 2024
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Benzinga - November 16th, 2024
- iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business - Simply Wall St - November 16th, 2024
- PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks - November 16th, 2024
- We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative - Yahoo Finance - November 16th, 2024
- Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest - Simply Wall St - November 16th, 2024
- APHIS Announces Final Notice on Additional Exemptions for the Movement of Organisms Modified or Produced Through Genetic Engineering - USDA APHIS - November 16th, 2024
- Adaptimmune nears second approval for TCR-T therapy - European Biotechnology News - November 16th, 2024
- Lundbeck reports 18% revenue growth in third quarter - The Pharma Letter - November 16th, 2024
- BioNTech to boost oncology offering with buy of Biotheus - The Pharma Letter - November 16th, 2024
- Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance - November 16th, 2024
- WPI Receives Federal Funding to Address Anticipated Demand for Biology and Biotechnology Professionals and Educators - WPI News - November 3rd, 2024
- Jonathan Dinman to Direct the Institute for Bioscience and Biotechnology Research - College of Computer, Mathematical, and Natural Sciences - November 3rd, 2024
- PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of "Buy" by Analysts - MarketBeat - November 3rd, 2024
- COP16, DSI mechanism for benefit sharing from the use of digital sequence information approved - Renewable Matter - November 3rd, 2024
- Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029 with 19.1% CAGR | MarketsandMarkets - PR Newswire - November 3rd, 2024
- Axonis Therapeutics raises $115 million in Series A financing - The Pharma Letter - November 3rd, 2024
- Regeneron third-quarter 2024 earnings top expectations - The Pharma Letter - November 3rd, 2024
- AbbVie inks up to $1.4 billion deal with EvolveImmune - The Pharma Letter - November 3rd, 2024
- CEO and Chairman of the Executive Board - European Biotechnology News - November 3rd, 2024
- The transformative potential of biotechnology and AI in healthcare - The Armchair Trader - November 3rd, 2024
- U.S. Biotechnology And Pharmaceutical Services Outsourcing Market Size to Reach USD 16.68 Billion By 2033 - BioSpace - October 6th, 2024
- Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance - October 6th, 2024
- Resolution Therapeutics scores 63.5 million in series B round - The Pharma Letter - October 6th, 2024
- Wiregrass Institute for Biotechnology welcomes local military veteran from Southeast Health as its first computational biologist - AOL - October 6th, 2024
- Generating and characterizing a comprehensive panel of CHO cells glycosylation mutants for advancing glycobiology and biotechnology research -... - October 6th, 2024
- Sapience Therapeutics Announces Participation at the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum - PR Newswire - October 6th, 2024
- Spyre Therapeutics lures Abivax exec to be its CMO - The Pharma Letter - October 6th, 2024